Abstract
The adoptive transfer of synthetic siRNA-mediated cblb-depleted autologous CD8(+) T cells acts as a potent adjuvant for dendritic cell (DC) vaccination and provides a significant therapeutic benefit. Our proof-of-concept study validates the strategy of inhibiting CBLB as a rational approach to augment the effectiveness of adoptively transferred immune cells.